Zimmer Biomet Holdings, Inc. with ticker code (ZBH) now have 24 market analysts covering the stock. The analyst consensus now points to a rating of ‘hold’. The target price High/Low ranges between $150.00 and $99.00 suggesting an average Analsyt target price of $128.75. Given that the stocks previous close was at $112.50 this would indicate that there is a potential upside of 14.4%. The day 50 moving average is $109.92 and the 200 day moving average is $125.82. The market cap for the company is 23.59B. The stock price for the company is currently $112.90 USD
The potential market cap would be $27,001,971,098 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 49.96, revenue per share of $34.79 and a 4.24% return on assets.
Zimmer Biomet Holdings, Inc. is a global medical technology company. Its segments include Americas, EMEA, and Asia Pacific. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic (CMFT) products; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its other product category primarily includes its robotic, surgical and bone cement products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee, and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System, and G7 Acetabular System. Its S.E.T. product category includes sports medicine, biologics, foot and others.
